HI-Bio: A Biogen Company’s Post

Excited to present at ASN Kidney Week 2023 (2nd Nov) on our Mission Therapeutics abstract titled "MTX652, a Novel Selective USP30 Inhibitor for the Treatment of Acute Kidney Injury (AKI): Phase 1 Results in Healthy Subjects and Model-Driven Human Efficacious Dose Projections." I'd be very happy to catch up with colleagues there, so let me know if you are attending! #ASNKidneyWeek2023 #MTX652 #AKI #ClinicalTrial #MissionTherapeutics

Modified pancreaticoduodenectomy: A viable alternative to hepatopancreaticoduodenectomy for middle-third cholangiocarcinoma by Onoe S, Mizuno T (...) Ebata T et 7 al. in HPB (Oxford)

The role of octreotide on renal function in patients with advanced cirrhosis #EurekaMag

Finally. Hopefully this is truly transformative. As Karin points out both in terms of “xenotransplantation” per se and the introduction of “novel immunomodulators”.

#PRESS: The Indian drug regulatory authority has approved Jardiance® (empagliflozin) 10mg tablets to reduce the risk of sustained decline in eGFR (only for patients with eGFR 30-90 ml/min/1.73sqm), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. This indication approval allows the nephrologists and cardiologists to use Jardiance 10mg tablets for the treatment of CKD in the eligible patients and help relieve burden on healthcare systems by reducing the risk of hospitalizations, as well as delaying progression to kidney-failure that necessitates dialysis or kidney transplantation. At Boehringer Ingelheim, we are solemnly committed to transforming lives of the patients, by bringing innovative therapies to help our physicians, optimally address the medical needs of our country! Learn more about it here https://lnkd.in/eADYqMtH #Kidneydisease #HealthcareInnovation

Dupilumab: VOYAGE of discovery leading to a further EXCURSION https://lnkd.in/ef9aQJfh

The LIPOSORBER team will be in Philadelphia on Nov 2-5 for ASN's Kidney Week Annual Meeting. Make sure to stop by our booth (506) to learn about how treatment with LIPOSORBER has enabled nearly 50% of steroid-resistant primary FSGS patients to attain complete or partial remission.* Ref: Muso, Eri et al. “Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.” Clinical and experimental nephrology vol. 19,3 (2015): 379-86. doi:10.1007/s10157-014-0996-8. *Serum lipid levels and outcomes in each treatment group were compared after approximately 6 years. Based on study that took place over two (2) years. #ASN2023 #kidneywk

Dupilumab: VOYAGE of discovery leading to a further EXCURSION https://lnkd.in/ef9aQJfh

MASH is the newest area of intervention in metabolic health. Earlier this year, Rezdiffra (resmetirom) was launched, but at $48K a year and with very minimal results, there is still a lot to be desired. #GLP1 are also under the microscope in this space. Lilly released information on their trial this past week- https://lnkd.in/gT88XYuD And more novel therapies to come: https://lnkd.in/gKKQ84h7 https://lnkd.in/gkCZAfkU Lots to watch in this space over the next few years! #Pharmacists #Pharmacybenefits #liver #newdrugapproval #GLP1

Nephrology towards precision medicine through nucleic acid therapeutics! ERA G&K aims to learn how this changes the landscape of patient care in both PH1 and kidney medicine in general. We would like you to contribute and fill the survey (explicitly NOT only but also for PH1 experts): https://bit.ly/433iqVT